Effects of etelcalcetide on fibroblast growth factor 23 in patients with secondary hyperparathyroidism receiving hemodialysis

BACKGROUND: Etelcalcetide is an intravenous calcimimetic approved for treatment of secondary hyperparathyroidism (sHPT) in patients receiving hemodialysis. Besides lowering parathyroid hormone (PTH), etelcalcetide also significantly reduces fibroblast growth factor 23 (FGF23), but the mechanisms are...

詳細記述

保存先:
書誌詳細
出版年:Clin Kidney J
主要な著者: Wolf, Myles, Block, Geoffrey A, Chertow, Glenn M, Cooper, Kerry, Fouqueray, Bruno, Moe, Sharon M, Sun, Yan, Tomlin, Holly, Vervloet, Marc, Oberbauer, Rainer
フォーマット: Artigo
言語:Inglês
出版事項: Oxford University Press 2019
主題:
CKD-Mdb
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7025329/
https://ncbi.nlm.nih.gov/pubmed/32082556
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ckj/sfz034
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料